Compare GEMI & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | AGMB |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | Belgium |
| Employees | 650 | 62 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.3M | 664.8M |
| IPO Year | N/A | N/A |
| Metric | GEMI | AGMB |
|---|---|---|
| Price | $4.09 | $14.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $8.31 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.0M | 62.2K |
| Earning Date | 05-14-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.05 | N/A |
| Revenue Next Year | $39.56 | $17.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.74 | $8.75 |
| 52 Week High | $34.67 | $17.82 |
| Indicator | GEMI | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 54.95 |
| Support Level | N/A | $9.54 |
| Resistance Level | $4.87 | $14.19 |
| Average True Range (ATR) | 0.27 | 0.99 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 21.24 | 61.84 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.